Saturday 7 November 2026
Export IMCR’s income statement to Excel — free account
Immunocore Holdings PLC Sponsored ADR
IMCR Healthcare Biotechnology
Immunocore Holdings PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $400.0 million, up 29.0% from fiscal 2024.
- Revenue
- −1.42%
- EPS
- −7,900.0%
- Free cash flow
- +441.0%
- Total debt
- +0.55%
Quarter to September 2026, against a year earlier
30.90
2.50
+8.80%
Follow IMCR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 3 | 3 |
| (9.58%) | (7.14%) | (4.47%) | (7.87%) | ||
| (3.42%) | (2.63%) | (1.64%) | (2.88%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(4.66%) | (3.55%) | (2.18%) | (3.80%) | |
Average Days of Receivables |
67.50 | 71.68 | 80.79 | 74.85 | |
Free Cash Flow per Share |
(0.30) | (0.61) | (0.81) | (0.35) | |
Free Cash Flow |
(15.05) | (30.74) | (41.15) | (18.20) | |
Capital Expenditures |
(4.34) | (5.82) | (6.19) | (7.79) | |
| Other line items | |||||
Cash ROIC |
(0.92%) | (1.88%) | (2.43%) | (1.06%) | |
Accounts Receivable Turnover |
5.84 | 5.73 | 5.22 | 5.24 | |
Accounts Payable Turnover |
0.21 | 0.16 | 0.19 | 0.22 | |
Inventory Turnover |
0.83 | 0.62 | 0.72 | 0.75 | |
Average Days of Payables |
1,748.15 | 2,346.97 | 2,027.53 | 1,592.64 | |
Days of Inventory on Hand |
483.75 | 642.29 | 600.19 | 556.10 | |
Tax Rate |
0.86 | 1.31 | 5.62 | 0.88 | |
Research and Development Expense of Revenue |
68.71% | 67.71% | 66.03% | 67.22% | |
Selling, General and Administrative Expense of Revenue |
41.35% | 39.50% | 38.11% | 38.40% | |
Share Based Compensation of Revenue |
9.42% | 8.36% | 7.87% | 7.87% | |
Interest Coverage |
(3.73) | (2.83) | (1.85) | (2.37) | |
Operating CF/Net income |
0.30 | 0.90 | 1.93 | 0.32 | |
Depreciation/Fixed assets |
0.28 | 0.28 | 0.28 | 0.28 | |
Capex/Depreciation |
(1.33) | (1.73) | (1.72) | (1.99) | |
Revenue per Share |
7.95 | 8.13 | 8.45 | 8.33 | |
Operating CF per Share |
(0.21) | (0.49) | (0.69) | (0.20) | |
Capex per Share |
(0.09) | (0.11) | (0.12) | (0.15) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.02 |
Columns are period end dates · fundamentals updated 6 Nov 2026